Johnson & Johnson JNJ

$253.91 +5.30 (2.13%)

Valuation

Market cap
599,124,736,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
24.28
Forward PE
23.79
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,662,000
Avg volume
6,764,354
Day's range
$248.50 – $253.94
Shares out
2,409,898,000
Stochastic %K
45%
Beta
0.21
Analysts
Strong Sell
Price target
$282.76

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

No headlines yet.

Stocktwits

chursinow62 Oct 15, 2:23 PM
$JNJ While lenders and money facilities dry up when it comes to the tech build - out JNJ is the safe haven because we haven’t even seen the tech sell off and destruction it will leave behind. Money is expensive to lend as is tech companies bonds. Downward spiral is starting to happen . LOAD this defensive AAA rated name to your portfolios JNJ 🔼🔼🔼🔼
0 replies
chursinow62 Oct 15, 1:59 PM
$JNJ Hedge funds bidding this up. Looking for places to hide from the down turn in Tech $270 quick
1 replies
TearsForFear Oct 15, 1:59 PM
$IBRX Once get BCG Naive will be a bladder cancer First line treatment with hhuge monopoly puttin $MRK and $JNJ out to pasture for bladder cancer treatments/indications. Race is on! BTW how you like $XBI rally as ai trade unwinds $TECL not so soog today
0 replies
Kosmos709 Oct 15, 1:58 PM
$JNJ Anyone panic sell on Monday?
0 replies
chursinow62 Oct 15, 1:35 PM
$JNJ Large institutional houses , ETFs , known hedge fund individuals are loading up big time here in the early trade. Some one knows something. My advice is jump in here NOW
0 replies
JFais Oct 15, 12:38 PM
Housekeeping note: I am going to try to add a Q&A section to Weekly Recap, as many of you are asking some great questions and I think the group would benefit from seeing them as well (some of these will post on X/ Stocktwits as well where I think it adds value) Some will be more stock-specific (I love pushback on my ideas), such as people wanting more thoughts on competition in the menin space $SNDX $KURA $JNJ Others more personal I imagine, such as steps I take to stay positive in a tough environment Cheers all- look forward to seeing where this goes (or rather, where you take it)👍
0 replies
btdb Oct 15, 10:40 AM
$CRMD $NVDA $NOK $JNJ 1. No recession 2. No earnings problem 3. Treasuries dropping 4. What we’re seeing is pe compression Inflation due to tariffs, war, AI buildout and buying resilience. Cautiously expecting stabilization and continued growth of the economy. FWIW
0 replies
Duncan74 Oct 15, 9:36 AM
$JNJ $SLS $MRK This is Merck's war to lose, and J&J is the wolf at the door. If Johnson & Johnson captures the $SLS platform, Merck ($MRK) faces absolute oncological extinction.
1 replies